"This is changing the way we practice prostate cancer." ...

State data from 2018 through 2022 shows prostate cancer is the leading cancer diagnosis in Cuyahoga County, yet 77% of cases ...

Radiation therapy (also called radiotherapy) uses high-energy beams or subatomic particles to damage the DNA inside prostate cancer cells. After enough damage, the cells cannot multiply, and they die.

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

(iVillage Total Health) - Men who undergo androgen deprivation therapy to treat prostate cancer may be a greater risk of developing gum disease, a new study concluded. The prostate is a walnut-size ...

Pfizer Inc. PFE shares are up during Thursday’s trading session after the company shared data from Talzenna plus Xtandi’s investigational treatment regimen for HRR gene-mutated metastatic ...

GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...